anti-Mouse (Murine) CD180 antibody for Immunoprecipitation

Recommended CD180 Antibody (supplied by: Log in to see )

Antigen
CD180 Molecule (CD180) Antibodies
  • Ly78
  • CD180
  • LY64
  • RP105
  • F630107B15
  • CD180 molecule
  • CD180 antigen
  • Cd180
  • CD180
Reactivity
Mouse (Murine)
118
34
3
2
Host
Rat
71
49
17
Clonality
Monoclonal
Conjugate
This CD180 antibody is un-conjugated
13
12
11
5
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Application
Flow Cytometry (FACS), Immunoprecipitation (IP)
84
49
42
34
29
25
20
12
5
4
3
2
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Catalog No. ABIN2689037
Contact our Customer Service for availability and price in your country.

General

Antigen CD180 Molecule (CD180) Antibodies
Reactivity Mouse (Murine)
(118), (34), (3), (2)
Host Rat
(71), (49), (17)
Clonality (Clone)
Monoclonal   ( )
Conjugate This CD180 antibody is un-conjugated
(13), (12), (11), (5), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Application Flow Cytometry (FACS), Immunoprecipitation (IP)
(84), (49), (42), (34), (29), (25), (20), (12), (5), (4), (3), (2), (1)
Pubmed 7 references available
Supplier Log in to see

Product Details anti-CD180 Antibody

Target Details CD180 Application Details Handling References for anti-CD180 antibody (ABIN2689037) Images
Brand BD Pharmingen™
Characteristics The RP/14 antibody reacts with CD180, the "radioprotective" 105 kDa (RP105) antigen expressed on mature B lymphocytes. Like other members of the Toll-like Receptor (TLR) family, the extracellular region of CD180 contains tandem repeats of a leucine-rich motif flanked by regions containing conserved cysteines. These characteristic structural components of TLR may mediate protein-protein interactions and regulation of signal transduction involved in innate immune responses. Furthermore, CD180 associates with the secretory protein MD-1 on the cell surface. Cross-linking of cell-surface CD180 with the RP/14 antibody induces activation signals in B lymphocytes. Despite the expression of CD180 on lymphocytes of all strains tested (BALB/c, BALB/c.xid, C3H, C57BL/6, CBA/N, and 129/Sv), some strains (BALB/c.xid, C57BL/6.xid, CBA/N, 129/Sv, and 129/Ola) display deficient responses to that stimulatory effects of mAb RP/14. Two-color analysis of CD180 expression on splenic B lymphocytes. BALB/c splenocytes were stained with either purified rat IgG2a, κ isotype control mAb R35-95 (Cat. No. 553927, left panel) or purified mAb RP/14 (right panel) in the presence of Mouse Fc Block™ (purified anti-mouse CD16/CD32 mAb 2.4G2, Cat. No. 553141/553142), followed by biotinylated anti-rat IgG2a mAb RG7/1.30 (Cat. No. 553894), then Streptavidin-PE (Cat. No. 554061) and FITC-conjugated anti-mouse CD45R/B220 mAb RA3-6B2 (Cat. No. 553087/553088). Flow cytometry was performed on a FACSCalibur™ .

BD Pharmingen™ Purified Rat Anti-Mouse CD180 - Purified - Clone RP/14 - Isotype Rat IgG2a, κ - Reactivity Ms - 0.5 mg
Purification The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
Immunogen BALB/c mouse splenocytes
Clone RP-14
Isotype IgG2a, kappa
Plasmids, Primers & others

Target Details CD180

Product Details anti-CD180 Antibody Application Details Handling References for anti-CD180 antibody (ABIN2689037) Images back to top
Antigen
Alternative Name CD180 (CD180 Antibody Abstract)
Background Synonyms: RP105
Pathways Cellular Response to Molecule of Bacterial Origin, Toll-Like Receptors Cascades

Application Details

Product Details anti-CD180 Antibody Target Details CD180 Handling References for anti-CD180 antibody (ABIN2689037) Images back to top
Application Notes Optimal working dilution should be determined by the investigator.
Restrictions For Research Use only

Handling

Product Details anti-CD180 Antibody Target Details CD180 Application Details References for anti-CD180 antibody (ABIN2689037) Images back to top
Concentration 0.5 mg/mL
Buffer Aqueous buffered solution containing ≤0.09 % sodium azide.
Preservative Sodium azide
Precaution of Use This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C
Storage Comment Store undiluted at 4°C.

References for anti-CD180 antibody (ABIN2689037)

Product Details anti-CD180 Antibody Target Details CD180 Application Details Handling Images back to top
Product cited in:

Ogata, Su, Miyake, Nagai, Akashi, Mecklenbräuker, Rajewsky, Kimoto, Tarakhovsky: "The toll-like receptor protein RP105 regulates lipopolysaccharide signaling in B cells." in: The Journal of experimental medicine, Vol. 192, Issue 1, pp. 23-9, 2000

Corcoran, Metcalf: "IL-5 and Rp105 signaling defects in B cells from commonly used 129 mouse substrains." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 163, Issue 11, pp. 5836-42, 1999

Chan, Mecklenbräuker, Su, Texido, Leitges, Carsetti, Lowell, Rajewsky, Miyake, Tarakhovsky: "The molecular mechanism of B cell activation by toll-like receptor protein RP-105." in: The Journal of experimental medicine, Vol. 188, Issue 1, pp. 93-101, 1998

Miyake, Shimazu, Kondo, Niki, Akashi, Ogata, Yamashita, Miura, Kimoto: "Mouse MD-1, a molecule that is physically associated with RP105 and positively regulates its expression." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 161, Issue 3, pp. 1348-53, 1998

Yamashita, Miyake, Miura, Kaneko, Yagita, Suda, Nagata, Nomura, Sakaguchi, Kimoto: "Activation mediated by RP105 but not CD40 makes normal B cells susceptible to anti-IgM-induced apoptosis: a role for Fc receptor coligation." in: The Journal of experimental medicine, Vol. 184, Issue 1, pp. 113-20, 1996

Miyake, Yamashita, Ogata, Sudo, Kimoto: "RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 154, Issue 7, pp. 3333-40, 1995

Miyake, Yamashita, Hitoshi, Takatsu, Kimoto: "Murine B cell proliferation and protection from apoptosis with an antibody against a 105-kD molecule: unresponsiveness of X-linked immunodeficient B cells." in: The Journal of experimental medicine, Vol. 180, Issue 4, pp. 1217-24, 1994